XERIS BIOPHARMA HOLDINGS, INC. Deferred Tax Assets, in Process Research and Development
XERIS BIOPHARMA HOLDINGS, INC. (XERS) had Deferred Tax Assets, in Process Research and Development of $0 as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2026-03-02
- 2025-12-31: Deferred Tax Assets, in Process Research and Development $0.00.
- 2024-12-31: Deferred Tax Assets, in Process Research and Development $8.33M.
- 2023-12-31: Deferred Tax Assets, in Process Research and Development $6.29M.
- 2022-12-31: Deferred Tax Assets, in Process Research and Development $1.49M.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-02 |
| 2024-12-31 | $8.33M 10-K · filed 2026-03-02 |
| 2023-12-31 | $6.29M 10-K · filed 2025-03-06 |
| 2022-12-31 | $1.49M 10-K · filed 2024-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |